Large numbers of men could have missed a prostate cancer diagnosis due to Covid-19. Combine that with a rise in prostate cancer and the future looks grim. Ultimately, something in the prostate cancer diagnostic landscape needs to change: but what? The post Changing the Prostate Cancer Screening Landscape appeared first on MedCity News.
In this second of a two-part article, we’ll cover common obstacles and offer insights on how to overcome these barriers to achieve success in the healthcare market. The post Market Acceptance: Key Challenges for Health Tech appeared first on MedCity News.
This policy watch provides a short overview of the Department of Health and Human Services (HHS), describing its history, budget, organizational structure and its major programs and responsibilities.
DENVER — Outside HCA HealthONE Rose medical center, the snow is flying. Inside, on the third floor, there’s a flurry of activity within the labor and delivery unit. “There’s a lot of action up here. It can be very stressful at times,” said Kristina Fraser, an OB-GYN in blue scrubs. Nurses wheel a very pregnant…
PASADENA, Calif. — As Fernando Ramirez drove to work the day after the Eaton Fire erupted, smoke darkened the sky, ash and embers rained onto his windshield, and the air smelled of melting rubber and plastic. He pulled to the side of the road and cried at the sight of residents trying to save their…
By KIM BELLARD Gosh, who knew that Jan 13 would be an AI day, with at least three major announcements about “blueprints” for its development going forward? Of course, these days every day is an AI day; trying to take in all AI-related news can be overwhelming. But before some other AI news drowns them…
That is according to the FDA. Nature Reviews Drug Discovery summarizes the progress to date as follows. The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) approved 57 new therapeutic drugs (NTD) in 2024. This is slightly above the average of 53 NTDs per year for 2014–2024,…
AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer. The post AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast…
Many healthcare executives are applauding the list of additional drugs chosen for the Medicare Drug Price Negotiation Program, while some drug companies are opposing it. The post How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program appeared first on MedCity News.
Joel Keenan, M.D., owner of York Primary Care in Maine, describes new tools in his eClinicalWorks EHR that are saving him time